NEW YORK (GenomeWeb News) – Rosetta Genomics reported after the close of the market on Monday a sharp increase in revenues for the for the six-month period ended June 30, as the company expanded access to its suite of microRNA-based cancer diagnostics.

During the first half of 2013, Rosetta's revenues rose to $193,000 from $51,000 in the same period the year before.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Vivek Murthy is no longer the surgeon general of the US, the Associated Press reports.

People around the globe took to the streets to support science — some with signs.

Parents who learn of their increased genetic risk of disease also contend with telling their children about theirs, the New York Times writes.

In PLOS this week: loci linked to body mass index measurements, long non-coding RNA expression and urothelial carcinoma prognosis, and more.